Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | HAO2 | Q9NYQ3 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778570 | 0.85 | MAPK14 (0.41) | KMT2AGRM5MAPK14MAPK13CSNK1D | |
| SCHEMBL20027815 | 0.85 | ALDH1A1 (0.43) | KMT2AKDM4CKDM4EALDH1A1HPGD | |
| SCHEMBL4767678 | 0.84 | KDM4E (0.49) | KMT2APTGER1KDM4EALDH1A1HPGD | |
| SCHEMBL14711720 | 0.83 | NR1H2 (0.41) | KMT2AKDM4EALDH1A1HPGDTSHR | |
| SCHEMBL1257365 | 0.83 | KDM4E (0.48) | GRM5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6670463 | 0.74 | SMN1; SMN2 (0.58) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL12650762 | 0.73 | MAPK14 (0.44) | KMT2AKDM4CMAPK14MAPK13CSNK1D | |
| SCHEMBL15750461 | 0.72 | CSNK1D (0.51) | KMT2AMAPK14MAPK13CSNK1DCSNK1E | |
| SCHEMBL1257163 | 0.72 | CSNK1D (0.51) | BCL2L1BADKMT2AMAPK14MAPK13 | |
| SCHEMBL25268941 | 0.72 | MAPK14 (0.63) | MAPK14MAPK13CSNK1DCSNK1EMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
| EP-1705179-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 2006-09-27 | — | — | EP | disclosed |
| EP-1399441-B1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2004-10-28 | — | — | US | disclosed |
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM LIMITED (GB) | 2004-09-16 | — | — | US | disclosed |
| EP-1406897-A2 | COMPOUNDS | SmithKline Beecham plc (GB) | 2004-04-14 | — | — | EP | disclosed |
| EP-1399441-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002559-A2 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
| WO-2003002561-A1 | N-AROYL CYCLIC AMINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | BCL2L1 2337/4885BAD 1281/4885KMT2A 2031/4885 |
| US-20040180887-A1 | N-aroyl cyclic amine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | BCL2L1 3207/4885BAD 1582/4885KMT2A 924/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | BCL2L1 2337/4885BAD 1281/4885KMT2A 2031/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | BCL2L1 2337/4885BAD 1281/4885KMT2A 2031/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | BCL2L1 2337/4885BAD 1281/4885KMT2A 2031/4885 |
| US-20040215014-A1 | Piperidine compounds for use as orexin receptor antagonist | HCRTR2, HCRTR1, OXTR | BCL2L1 3121/4885BAD 558/4885KMT2A 949/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | BCL2L1 2337/4885BAD 1281/4885KMT2A 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.